A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors

Joshua B. Rubin, Andrew L. Kung, Robyn S. Klein, Jennifer A. Chan, Yan Ping Sun, Karl Schmidt, Mark W. Kieran, Andrew D. Luster, Rosalind A. Segal

Research output: Contribution to journalArticle

515 Scopus citations


The vast majority of brain tumors in adults exhibit glial characteristics. Brain tumors in children are diverse: Many have neuronal characteristics, whereas others have glial features. Here we show that activation of the G i protein-coupled receptor CXCR4 is critical for the growth of both malignant neuronal and glial tumors. Systemic administration of CXCR4 antagonist AMD 3100 inhibits growth of intracranial glioblastoma and medulloblastoma xenografts by increasing apoptosis and decreasing the proliferation of tumor cells. This reflects the ability of AMD 3100 to reduce the activation of extracellular signal-regulated kinases 1 and 2 and Akt, all of which are pathways downstream of CXCR4 that promote survival, proliferation, and migration. These studies (i) demonstrate that CXCR4 is critical to the progression of diverse brain malignances and (ii) provide a scientific rationale for clinical evaluation of AMD 3100 in treating both adults and children with malignant brain tumors.

Original languageEnglish
Pages (from-to)13513-13518
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number23
StatePublished - Nov 11 2003

Fingerprint Dive into the research topics of 'A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors'. Together they form a unique fingerprint.

Cite this